Company Overview and News

Safe Orthopaedics, SA: Strong Acceleration In Growth During Q1 2017

2017-05-09 devicespace
“Following a good performance in the fourth quarter of 2016, the pace of our expansion has continued to accelerate—both in France and in the Rest of the world. That confirms the effectiveness of our new strategy, which has delivered clear benefits after just over six months”
Upvote Downvote

Safe Orthopaedics, SA Reports Its Full-Year Results for 2016

2017-04-28 devicespace
“2016 marked a change in Safe Orthopaedics’ strategy. Thanks to our decision to withdraw from the United States to refocus in priority on the European market, we successfully managed to reduce our cash consumption in less than a year, while also delivering growth, as demonstrated by our fourth-quarter 2016 performance”
Upvote Downvote

Pascale Davis., An Internationally Renowned Expert On The Spine Market, Joins Safe Orthopaedics, SA As Global Head Of Marketing

2017-04-24 devicespace
“It gives us great pleasure to welcome Pascale to Safe Orthopaedics. Her arrival illustrates the Company’s ability to attract well-known international talents and the growing interest in its technology, as was recently demonstrated by AP-HP’s decision to list our products”
Upvote Downvote

Safe Orthopaedics, SA Products Listed By Paris Hospitals

2017-04-10 devicespace
“A Randomized Study Confirms the Benefits of Safe Orthopaedics’ Products in a Leading French Teaching Hospital”
Upvote Downvote

Safe Orthopaedics, SA Expands Into Germany And Appoints As Head Of Sales Germany

2017-03-06 devicespace
SAFE ORTHOPAEDICS (Paris:SAFOR) (FR0012452746 – SAFOR), a company offering an innovative range of sterile implants combined with their single-use instruments for spinal surgery, is today announcing that it is expanding into Germany and has appointed Jochen Esser as Head of Sales Germany.
Upvote Downvote

Safe Orthopaedics, SA Offers New Technologies To Treat Traumatic Injuries Due To Osteoporosis Or Bone Metastases

2017-02-15 devicespace
“The solution proposed by Safe Orthopaedics improves considerably the options in Cypress screw fixation, by increasing its anchoring strength irrespective of bone quality, with the added possibility of injecting cement into the vertebra during the procedure.”
Upvote Downvote

Safe Orthopaedics Release: Company Reports Revenue Growth Of 10% In FY 2016*, With An Acceleration In The Fourth Quarter

2017-01-19 devicespace
Revenue up 26% Continuing growth of 18% in France Acceleration in the pace of growth in exports to 36%
Upvote Downvote

SafeOrthopaedics Release: Company Announces The Commercial Launch Of A Bone Substitute For Its Walnut Cervical Cage

2017-01-16 devicespace
“It dovetails perfectly with Safe Orthopaedics’ strategy of offering effective solutions, while providing the surgeon with flexibility in how to use it.”
Upvote Downvote

A Randomized Study Confirms The Benefits Of Products In A Leading French Teaching Hospital

2016-10-20 devicespace
“Our study brought to light the major savings achieved by using Safe Orthopaedics’ products for scheduled vertebral fusion surgeries. I am tremendously proud of the work that our teams did.”
Upvote Downvote

EuroSpine 2016: Safe Orthopaedics Invites Five Highly Regarded Surgeons To Share Their Experiences Of The Benefits Of Its Modular Technologies

2016-10-05 devicespace
“We are both proud and excited to see the growing interest among surgeons in Safe Orthopaedics, as reflected by these talks. By sharing their experiences of our products, they will demonstrate the relevance of our innovations firmly anchoring single-use instruments and MIS surgery at the heart of surgical practice.”
Upvote Downvote

BRIEF-Safe Orthopaedics issues new tranche of OCABSA for 500,000 euros

2016-05-24 reuters
* Safe Orthopaedics announces the issuance of a new tranche of OCABSA representing a total debt debenture of 500,000 euros ($560,650.00)
Upvote Downvote

Related Articles

LPCN: Lipocine Inc Analysis and Research Report

8h - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...